AbbVie (ABBV) News Today

AbbVie Inc. (NYSE: ABBV) shares have climbed as the company reported better-than-expected quarterly sales, raised its full‐year guidance and attracted a wave of analyst upgrades. Below are the key developments driving investor sentiment today:

• Positive Sentiment: Second-quarter revenues of $15.42 billion topped Street forecasts and led AbbVie to raise its full-year EPS guidance. Article Title
• Positive Sentiment: Skyrizi and Rinvoq sales surged—up 61.8% and 41.8% year-over-year—easing Humira’s 58.1% decline. Article Title
• Positive Sentiment: Morgan Stanley lifted its price target on ABBV to $255 (overweight), Guggenheim to $227 (buy) and Raymond James to $236 (outperform). Article Title
• Positive Sentiment: Potential $1 billion acquisition of Gilgamesh Pharmaceuticals would broaden AbbVie’s clinical-stage pipeline in neuroscience and psychedelics. Article Title
• Positive Sentiment: Several pipeline updates show promise—a Phase 3 lutikizumab study in hidradenitis suppurativa and multiple Phase 2 programs (mirvetuximab for ovarian cancer, ABBV-932 in anxiety, gastric cancer, and a real-world Parkinson’s trial). Article Title
• Neutral Sentiment: Analysts’ consensus remains a “moderate buy” based on 16 buys and 8 holds among 27 research firms. Article Title
• Neutral Sentiment: Former FDA chief Scott Gottlieb called the Trump administration’s drug-pricing letters “a good starting point,” but broader policy impact remains uncertain. Article Title
• Negative Sentiment: Adjusted EPS of $2.97 missed estimates of $3.24, reflecting an earnings-per-share shortfall despite the revenue beat. Article Title
• Negative Sentiment: An IL-1 inhibitor flopped in a Phase 2 ulcerative colitis trial, missing its primary endpoint and raising questions about that program’s prospects. Article Title